From: Regulation of microRNAs by epigenetics and their interplay involved in cancer
Epigenetically regulated miRNAs | Target protein | Cancer type | Epigenetic drug | Fold change | Citation |
---|---|---|---|---|---|
Down-regulated | Â | Â | Â | Â | Â |
miR-449 | CDK6, CDC25A, c-MET | Breast cancer | DZNep + TSA | >20 folds | [50] |
Hepatocellular carcinoma | TSA | 10-30 folds | [31] | ||
miR-125b | PIGF | Hepatocellular carcinoma | 5-Aza-CdR | >2 folds | [51] |
miR-126 | VEGFA, PIK3R2 | Bladder cancer | 5-Aza-CdR + PBA | >10 folds | [52] |
miR-127 | BCL6 | Bladder cancer and clear cell renal cell carcinomas | 5-Aza-CdR + PBA/TSA | >10 folds | |
miR-1-1 | FOXP1, MET, HDAC4 | Hepatocellular carcinoma | 5-AzaC | >20 folds | [43] |
miR-34 | C-MYC, CDK6, | Lung cancer, melanomas and prostate cancer | 5-Aza-CdR | >10 folds | |
miR-181a,b, miR-200a,b,c, and miR-203 | BMI1 and RING2 | Prostate cancer | DZNep/5-Aza-CdR/SAHA | 2-20 folds | [32] |
miR-31 | SRC, RAB27a, NIK and MET, RhoA and WAVE3 | Melanoma | 5-Aza-CdR/DZNep | >2 folds | [24] |
Breast cancer | 5-Aza-CdR or 5-Aza-CdR + TSA | >5 folds | [25] | ||
miR-29 | Mcl-1, DNMT3A, DNMT3B,SP1, Tcl-1, CDK6 and IGR1F | Aggressive B-Cell Lymphomas | DZNep + SAHA | 2-10 folds | [10] |
Chronic lymphocytic leukemia and acute myeloid leukemia | LBH589/SAHA/AR-42 | 2-5 fold | |||
miR-15a/miR-16 | BCL-2 and MCL-1 | Chronic lymphocytic leukemia | LBH589/SAHA | 2-5 fold | [16] |
miR-205 | SIP1 and ZEP | Prostate cancer | 5-Aza-CdR | >100 folds | [37] |
miR-21 | PDCD4, TPM1, and MARCKS | Prostate cancer | 5-Aza-CdR | >2 folds | [37] |
miR-370 | IRS-1 | Oral squamous cell carcinoma | 5-Aza-CdR | 2-20 folds | [56] |
miR-373 | MBD2 | Hilar cholangiocarcinoma | 5-Aza-CdR or 5-Aza-CdR + TSA | 2-5 folds | [57] |
miR-193b | ETS1, CCND1, PLAU | Prostate cancer | 5-Aza-CdR + TSA | >2 folds | [58] |
miR-132 | HB-EGF,TALIN2 | Prostate cancer | 5-Aza-CdR or 5-Aza-CdR + TSA | >5 folds | [59] |
miR-145 | BNIP3, TNFSF10,PAK7 | Prostate cancer and clear cell renal cell carcinomas | 5-Aza-CdR or 5-Aza-CdR + TSA | >2 folds | |
miR-141, miR-514 | HGF, CDC42, RBX1, SLC2A1 | Clear cell renal cell carcinomas | 5-Aza-CdR + TSA | >2 folds | [53] |
miR-335 | SOX4, Rb1 | Hepatocellular carcinoma | 5-Aza-CdR + TSA | >2 folds | [61] |
miR-205 | BCL-w | Prostate cancer | 5-Aza-CdR | 2-5 folds | [62] |
let-7 family | RAS | Nasopharyngeal carcinoma | Zebularine | 2-100 folds | [63] |
Up- regulated | Â | Â | Â | Â | Â |
miR-224 | API-5 | Hepatocellular carcinoma | C646 | <50% | [36] |
miR-17-92 Cluster | PTEN, BCL2L11, CDKN1A | Colorectal Cancer | SAHA or TSA | 25%-67% | [64] |